Osong, South Korea, July 6th, 2022
In-line with its constantly expanding collaborative and scientific base Naason Science announces that it will present a number of posters and scientific presentations at this years SfN. Along with participation in the exhibition Naason Science will also be present in a significant number of poster sessions and scientific sessions that reflect Naason’s ongoing attempts to create tools for drug discovery and to engage in collaboration with the global neuroscience community. Since travel has been greatly curtailed through COVID, Naason Science will use this years SfN to launch its strategy for providing high value/high comprehension preclinical services to drug discovery globally.
To highlight the importance of SFN as platform for scientific communication Dr Larry Park, Naason Science’s CEO said, “with this years SfN we will be able to present a great deal of new modelling platforms have emerged from our internal research and development over the last few years. These models range from refinement of existing neurological models to areas such as pain and ocular modelling that are non-less important when we take into account the overall effects of aging and human genetics on the human body. We see this years SfN as a prime springboard for communicating our continued intentions of becoming a global lead in the preclinical modelling of disease.”
Details on all of Naason Science’s activities at this years SfN will be announced closer to the event.
While working with 14 different international institutions is rewarding in itself, our collaboration being recognized by Frontiers is a source of pride and joy.
Access the article yourself and learn more about the emerging role of translational digital biomarkers within home cage monitoring technologies in preclinical drug discovery and development!
Naason Science Inc. and Biorchestra Inc. have signed Memorandum of Understanding for Scientific Partnership.
Both NAASON SCIENCE and BIORCHESTRA share a set of values and a vision that involves the alleviation of human suffering and the endeavor to search for cures for rare and orphan diseases. In addition, both companies have scientific missions that intersect in the area of next generation drug discovery and development as well as those areas where there are currently unmet medical needs or sub-optimal medical treatments.
For more information please contact us firstname.lastname@example.org
To serve our customers even better and faster we have upgraded our technical capabilities with Maldi-Tof and Simoa® for CSF collection and NfL biomarker detection.
With Simoa assays we can detect neurological biomarkers, such as Neurofilament Light (NfL), Tau, GFAP and several others associated with brain injury and disease. In MALDI Imaging, a laser scans tissue samples and a full MALDI spectrum is recorded at regular intervals.
For more information on how we have improved our services please contact us email@example.com
PTSD is a serious condition that can lead to intense fear, anxiety and depression. Current medication is unspecific, ineffective and has a vast number of side effects (sedation, abuse potential, sexual dysfunction). As a result, many people continue to suffer from PTSD in spite of current treatment options, indicating a critical need for new treatments.
One limiting factor in the development of treatment for PTSD is the lack of valid, translational models. Naason Science has been developing models of PTSD in the rat and has initiated a development program in a larger animal - the minipig, based on a multi-faceted prolonged stress paradigm, so as to test the efficacy of new compounds.
Naason Science is a CNS CRO established in Korea in 2017. Naason Science was established to target the global market from the beginning, and its partners are diverse not only in Korea but also in Europe, including Germany and the Netherlands, and Japan.
The ability to conduct and effectively ramp up operations during the COVID-19 crisis has made Naason Science one of the most dependable CRO’s on the globe.
Osong, South Korea, June 22nd, 2020
The global COVID-19 crisis is far from over but as populations around the world come to terms with the damage done and begin to repair and rebuild their personal and professional lives Naason Science stands at the front of drug discovery and development not having missed a beat.
During the COVID crisis Naason Science managed to initiate and complete more studies than perhaps any other global CRO. The research and development platform completed its validation of research models in the areas of AMD, DMD, ALS and diseases associated with chronic pain. What is perhaps more important was the fact that the Naason Science contribution to very important consortiums concerning PTSD and specific gene therapies was unbroken and all results and milestones were met during the crisis.
When Naason Science was formed the founders had a vision that the next generation of preclinical services would entail cutting edge technologies and models that provided greater insight and translatability to human diseases. However, in these times of crisis, we have also added to that vision the quality of dependability in the delivering of services in unforeseen and challenging circumstances. Naason Science believes that all lives matter – that is why we work so hard – in these times of global strife Naason Science will stand by its commitment to our collaborators and clients. We will stand by our staff and we will not compromise on our endeavour to create a workplace and a world that is inclusive and diverse.
In a final word we would like to say that we, the staff, scientists, and researchers of Naason Science stand by the need for diversity and understanding in todays world. We want to watch our families grow and prosper along with everyone else in a world that is based on understanding and inclusion. We will speak out against injustice whenever we see it - whether it be racial or otherwise.
Peace and Warmth to All and #blacklivesmatter
Osong, South Korea, March 20, 2020
Naason Science sends out its hopes that everyone takes all of the prescribed precautions and stays as safe as possible at this time. Nevertheless, we would also like to assure all of our local and global collaborators that we are not experiencing any disruption in business at this time. In many ways, the Korean people and the Korean health authorities have worked admirably to cope with the outbreak of COVID-19, and this has resulted in no disruptions in Naason Science´s ability to maintain its study schedules.
We remain vigilant and carry out all precautions in order to protect ourselves, our co-workers as well as our families and fellow citizens while, at the same time, we stay mindful of the fact that the work that we carry out in conjunction with our collaborators and our partners is of the ultimate importance to their aspirations. In the event that there would be a change in our current situation, we will contact all of our collaborators, clients and partners immediately and directly.
Since many of our ongoing projects have an effect on the health and wellbeing of people, we remain committed to all of the work that we are performing and, in fact, have ramped up our capabilities to accommodate additional investigations.
For additional information please contact firstname.lastname@example.org
Naason Science CEO Larry Park was interviewed to 7CJB News during visit of President Moon to KBio New Drug Development Center .
Larry´s comments at 1:30 min.
English subtitles coming soon!
Naason Science has recently completed validation of the models within it’s Orthopedic modelling platform. These models include models for primary and secondary (post-traumatic, congenital etc.) OA. All models can combine MRI and CT micro-CT. The models are available in a variety of species.
The models are:
▪ Surgical model for ACLT
▪ Surgical model for Meniscectomy (MMT)
▪ Collagenase Injection
▪ Sodium monoiodoacetate /MIA
▪ Crystallin alpha B KO mouse model
The models can incorporate histopathology and biochemical analysis as we all as imaging as well as 24/7 home-cage monitoring for:
▪ General locomotion
▪ Circadian Rythm
▪ Anticipatory behaviour
▪ Social distancing – anxiety & depression
▪ Climbing/rearing behaviour
▪ Gait Analysis
For more information about our Modelling Platform for Osteoarthritis please contact email@example.com.
Copyright Naason Science
Osong, South Korea, July 10, 2019 - Addex Therapeutics announced July 9 that it will lead a consortium for the development of small-molecule negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 7 (mGlu7) as a potential treatment to reduce fear memory in post-traumatic stress disorder (PTSD). The project, named DiSARM FEAR, has been awarded a €4.85 million Eurostars grant to cover research activities performed by all participants, including Naason Science (South Korea), Endotherm (Germany), Nucro Technics (Canada) and Radboud University (Netherlands), in addition to Addex.
PTSD is a serious anxiety disorder that can lead to intense fear and anxiety. Current medication is unspecific and ineffective, with a number of side effects. By selectively targeting mGlu7 with NAMs, the brain circuitries involved in fear and anxiety can be precisely modulated, potentially resulting in higher efficacy and fewer side effects.
The project will capitalize on the significant discovery and preclinical investigations already achieved at Addex, including preclinical studies performed using ADX71743, a prototypical selective mGlu7 receptor NAM identified and characterized by Addex (Kalinichev et al. 2013. J.Pharmcol.Exp. Ther. 344, 624-636). Published and unpublished data generated with this compound in preclinical models demonstrates the central role of mGlu7 receptors in key processes involved in fear memory. The DiSARM FEAR project aims to generate novel mGlu7 NAMs ready to enter IND enabling studies within 3 years.
Naason Science’s CSO Jonathan Friedman said of the project, “Naason’s inclusion within the consortium confirms the expertise and acumen we have been building in the area of modelling neurological and psychiatric disorders over the last few years. We are delighted to be able to collaborate with Addex and the other consortium members to quickly and effectively complete the preclinical work and facilitate the IND enabled studies in an area where there is a significant global unmet clinical need”.
“This important research not only advances a potential new avenue in PTSD but could provide insight to other neurological disorders,” said Tim Dyer, CEO of Addex. “This project is another example of our strategy to leverage non-dilutive funding and a collaborative approach to maximize the value of our unique allosteric modulation discovery platform technology, potentially leading to multiple new products for our pipeline.”
About Naason Science: Naason Science is a global leader in contract and collaborative research aimed at preclinical drug development in a variety of therapeutic areas. Naason´s various preclinical modelling platforms are customized to suit the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a toolbox of state-of-the-art technologies that allow for rapid and effective testing of preclinical drug candidates.
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
May 20, 2019 - Naason Science is now offering Efficacy Evaluation of Compounds in a Rat Model of Dry Eye Disease. The objective of the model to investigate whether the compound has an anti-dry eye syndrome effect in a Rat Model of Dry Eye Disease induced by Extraorbital Lacrimal Gland Excision (ELGE).
In our pilot study ELGE surgery was performed after the body weight was measured on day 1. The test substance was administered in eyeballs and treatments were continued for 14 days after 1 week of ELGE surgery. The Schirmer test on the rats’ both left and right eyes were carried out to measure basal and reflective tear secretion. The efficacious effects of compounds were compared also to Xiidra® (Shire US Inc, USA) as FDA approved eye drop syndrome agent.
For more information about our Rat Model for Dry Eye Disease please contact firstname.lastname@example.org.